Clinical Trials
2
0 active
Approvals
2
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
Completed
1
50.0%
Recruiting
1
50.0%
- AVITA Medical's Board of Directors has appointed Cary Vance as President and Chief Executive Officer effective immediately, following his successful six-month tenure as Interim CEO since October 2025. - The appointment follows a thorough search process conducted with an international executive search firm, with the Board unanimously concluding that Vance is the right leader for the company's growth period. - Vance brings 30 years of healthcare executive experience and has demonstrated decisive leadership in stabilizing the business, sharpening strategic focus, and rebuilding confidence among employees, customers, and shareholders. - Jan Stern Reed has been elected as Chair of the AVITA Medical Board, bringing over 35 years of legal and business management experience in the healthcare industry.
- Protalix BioTherapeutics has appointed Gilad Mamlok as Senior Vice President and Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin. - Mamlok brings three decades of experience in healthcare and technology companies, including roles at TytoCare, Sol-Gel Technologies, and Given Imaging. - The appointment comes as Protalix continues to advance its pipeline of plant cell-based therapeutic proteins, including approved products Elfabrio and taliglucerase alfa. - The company's proprietary ProCellEx platform represents the first FDA-approved protein production system using plant cell-based suspension expression technology.
